Pazopanib Activity In Pancreatic Neuroendocrine Tumors (Pnets)

e15171 Background: The PAZONET trial analysed the efficacy and safety of the use of pazopanib (800 mg/qd) in patients (pts) with progressive metastatic NETs that had been previously treated with other novel targeted agents. Here we report the clinical outcome of those patients with pNETs treated with pazopanib. Methods: Fourty-four pts with locally-advanced or metastatic gastrointestinal or pancreatic NET with disease documented as progressive were treated at the PAZONET trial. Pazopanib 800 mg was given daily until disease progression (DP) or unacceptable toxicity. Within this substudy we have analysed the clinical outcome of those patients with pNETs compared with those without pancreatic primary origin. Results: 17 pts with pNETs were recruited. Median PFS in pNETs (12.8 [11.0-14.6]) was significantly longer than in gastrointestinal NETs (GINETs) (10.0 mo [4.9-15.1]) vs other primary tumors (Non-GEP-NETs) (3.4 mo [0.0-7.0]). Two pts had PR (11.8%), 10 SD (58.8%), and 5 DP (29.4%). Clinical benefit rate...